🏢 公司NewsroomKURACodex · 实盘不做把握 9/10
北京时间·🕒 发布 19:30:39(美东 07:30)·⟳ 抓取 19:34:54 +4m15s·⚡ 决策 08-05 22:02:31 +2h27m·82.9 天前
Kura Oncology宣布将于8月12日盘后披露二季度财报并召开电话会
本次只是公司官方披露财报发布时间和电话会安排，未包含收入、利润、指引、临床、监管或商业化新增事实。
📄 原文KURA↗ 原文
Kura Oncology to Report Second Quarter Financial Results
SAN DIEGO , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed…
不做 Kura Oncology（KURA.US）
仅为财报发布时间和电话会安排公告，没有业绩数据、指引变化、临床进展或监管事件，方向不明且无法形成同向交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-05 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是公司官方披露财报发布时间和电话会安排，未包含收入、利润、指引、临床、监管或商业化新增事实。
主要风险
- 财报本身可能在2026-08-12盘后形成新催化，但当前日程预告不提供方向性交易依据。
原文全文
展开原文 · 1,483 字
SAN DIEGO
,
Aug. 05, 2026
(GLOBE NEWSWIRE) --
Kura Oncology, Inc.
(Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report its second quarter 2026 financial results after the close of the
U.S
financial markets on
Wednesday, August 12, 2026
.
Kura’s management will host a webcast and conference call at
4:30 p.m. ET
/
1:30 p.m. PT
to discuss the results and provide a corporate update.
The live webcast and archived replay of the event may be accessed on the Company’s website at
www.kuraoncology.com
under the Investors tab in the Events and Presentations section.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at
https://kuraoncology.com/
and follow us
X
and
LinkedIn
.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
,
Aug. 05, 2026
(GLOBE NEWSWIRE) --
Kura Oncology, Inc.
(Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report its second quarter 2026 financial results after the close of the
U.S
financial markets on
Wednesday, August 12, 2026
.
Kura’s management will host a webcast and conference call at
4:30 p.m. ET
/
1:30 p.m. PT
to discuss the results and provide a corporate update.
The live webcast and archived replay of the event may be accessed on the Company’s website at
www.kuraoncology.com
under the Investors tab in the Events and Presentations section.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at
https://kuraoncology.com/
and follow us
X
and
.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。